Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Gynecol Oncol. 2013 May 28;130(3):629–633. doi: 10.1016/j.ygyno.2013.05.028

Table 3.

Summary of anti-HE4 antibodies and HE4 in serum and urine from patients with clinical evidence of stage III or IV OvC at the time of assay.

Patient Anti-HE4 antibodies (mean OD) #     HE4 antigen (pM)
Dilution 1:20 Dilution 1:100 Serum Urine
1 0.63 0.57 439* 11.5*
2 0.29 0.18 180* 11.9*
3 0.03 0 116 7.0*
4 3.51* 3.65* 90 9.1*
5 1.70* 2.61* 652* 16.9*
6 0.01 0.09 665* 46.4*
7 0.10 0.21 492* 15.6*
8 0.30 0.16 71 1.5
9 0.65 0.39 73 2.2*
10 2.69* 1.38* 176* 8.1*
11 0.30 0.23 337* 4.9*
12 0 0 82 1.7
13 2.49* 2.93* 205* 2.2*
#

Cut-off values were the same as for the data presented in Table 2 and adsorption values corresponding to M+2 SD are indicated (*).

##

Sera were scored as positive for HE4 antigen using the 150 cutoff established for the FDI kit. Urine samples were assayed as described [42] and scored as positive (M+2SD) at a cut-off value of 2.0.